Artiva Biotherapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ARTV Nasdaq 2830 www.artivabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights - Mar 10th, 2026 2:05 pm
Artiva Biotherapeutics Pivots to Rheumatoid Arthritis at TD Cowen, Teases 2026 RA Data Update - Mar 4th, 2026 1:13 pm
Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - Feb 25th, 2026 6:00 am
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant - Feb 24th, 2026 6:00 am
AtaiBeckley names Michael Faerm as finance chief - Feb 19th, 2026 6:21 am
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors - Feb 19th, 2026 6:00 am
Undervalued Penny Stocks To Consider In January 2026 - Jan 26th, 2026 11:05 am
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL - Jan 21st, 2026 6:00 am
Artiva Biotherapeutics (ARTV): Evaluating Valuation After CEO’s Latest Insider Share Sale - Dec 19th, 2025 4:14 pm
Rocket Pharmaceuticals Leads Our Trio Of Penny Stock Contenders - Dec 17th, 2025 5:04 am
Wedbush Predicts Up to ~600% Jump for These 2 ‘Strong Buy’ Stocks - Dec 14th, 2025 4:05 am
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease - Nov 12th, 2025 5:20 am
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Nov 12th, 2025 5:00 am
Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK® - Nov 3rd, 2025 2:05 pm
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November - Oct 30th, 2025 2:17 pm
3 Promising Penny Stocks With Market Caps Under $200M - Oct 29th, 2025 12:04 pm
Artiva Biotherapeutics Prioritizes Refractory Rheumatoid Arthritis as Lead Indication for AlloNK (AB-101) - Oct 22nd, 2025 5:41 am
Artiva Biotherapeutics (ARTV): Valuation Snapshot Following FDA Fast Track for AlloNK in Refractory Rheumatoid Arthritis - Oct 20th, 2025 6:05 am
Artiva Biotherapeutics (ARTV) Is Up 113.9% After FDA Fast Track for AlloNK in Refractory RA – Has the Bull Case Changed? - Oct 19th, 2025 5:11 am
Top Midday Gainers - Oct 17th, 2025 11:58 am